The medical facility of German pharmaceutical giant Fresenius Kabi in Wuhan Biolake finished its trial production of first batch antineoplastic injection on April 23, 2015.
The facility could be officially put into production as early as September after national drug examination and approval. It will produce three million bottles of antineoplastic injection annually during the first phase, with an annual output value of one billion Yuan (US$ 161.4 million).
This is the first medical facility with production lines of the eight world’s top 500 pharmaceutical companies in Wuhan Biolake. With a construction investment of 200 million Yuan (US$ 32.28 million), it’s also the only antineoplastic production base of Fresenius Kabi in China.
It’s so far the most advanced medical production line in China. Its products will not only be available in Chinese market, but also be exported to Europe and America.
The annual output is expected to reach eight million in the future, with production value of three billion Yuan (US$ 484.2 million).
The annual output is expected to reach eight million in the future, with production value of three billion Yuan (US$ 484.2 million).
No comments:
Post a Comment